Factor XI
Factor XI
Factor XI is an important protein in the blood coagulation cascade, and is part of the intrinsic coagulation pathway. As a zymogen, Factor XI circulates in an inactive form in the blood. When blood vessels are damaged, Factor XI is activated to Factor XIa, which then activates Factor IX, leading to the activation of Factor X. This cascade ultimately generates thrombin, promoting blood clotting, sealing the blood vessel damage, and stopping bleeding.
Factor XI is crucial for maintaining normal hemostatic function, but abnormal activity can lead to bleeding or thrombosis. Factor XI deficiency (Hemophilia C) is a genetic disorder that predisposes individuals to spontaneous or trauma-induced bleeding. On the other hand, excessive Factor XI activity is associated with thrombosis and may increase the risk of deep vein thrombosis, pulmonary embolism, and stroke[1].
All Product Categories
-
Factor XI Related Products (19)
Related Products (19)
- 1
-
Frunexian
0 ImagesCat. No.: HY-156613CAS No.: 1803270-60-1Synonyms: EP-7041Frunexian (EP-7041) is a selective and potent inhibitor of coagulation factor XI/activated factor XI, targeting to factor XIa. Frunexian exhibits antithrombotic activity, with no bleeding liability in rat mesenteric arterial puncture model. Frunexian can be used in extracorporeal membrane oxygenation (ECMO) research.
-
Pyr-Pro-Arg-pNA (hydrochloride)
0 ImagesSynonyms: S-2366 (hydrochloride)Pyr-Pro-Arg-pNA (S-2366) hydrochloride is a chromogenic peptidyl substrate, and a noncompetitive inhibitor that occupies the active sites of FXIa and FXIa-LC to block factor IX activation. Pyr-Pro-Arg-pNA hydrochloride functions as a hydrolyzable substrate for FXIa’s catalytic domain, human APC, murine APC, and purified plasma kallikrein.
-
ISIS 416858
0 ImagesCat. No.: HY-134005CAS No.: 1223657-78-0Synonyms: FXI-ASO; BAY2306001; IONIS-FXIRxISIS 416858, a single-stranded antisense oligodeoxynucleotide, is a potent and selective inhibitor of FXI mRNA expression.
-
Vortosiran
0 ImagesCat. No.: HY-177669CAS No.: 3061406-99-0Synonyms: RBD4059Vortosiran (RBD4059) is a siRNA that inhibits the synthesis of coagulation factor XI (FXI). Vortosiran shows potent inhibitory activity against mouse FXI transcripts with an IC50 of 69 pM; it exerts similar effects on common FXI transcripts from humans and monkeys, with an IC50 of 59 pM. Vortosiran exhibits antithrombotic activity without impairing hemostatic function. Vortosiran can be used in research related to intravascular thrombosis.
-
Cenvacibart
0 ImagesSynonyms: REGN-7508
-
Vortosiran sodium
0 ImagesCat. No.: HY-177669ASynonyms: RBD4059 sodiumVortosiran (RBD4059) sodium is a siRNA that inhibits the synthesis of coagulation factor XI (FXI). Vortosiran sodium shows potent inhibitory activity against mouse FXI transcripts with an IC50 of 69 pM; it exerts similar effects on common FXI transcripts from humans and monkeys, with an IC50 of 59 pM. Vortosiran sodium exhibits antithrombotic activity without impairing hemostatic function. Vortosiran sodium can be used in research related to intravascular thrombosis.
-
BMS-962212 hydrochloride
0 ImagesCat. No.: HY-117290ACAS No.: 1430115-97-1BMS-962212 hydrochloride is a selective coagulation factor XIa inhibitor and acute antithrombotic agent. BMS-962212 hydrochloride can be used in the research of thrombosis.
-
FAM labled Vortosiran sodium
0 ImagesCat. No.: HY-177669CSynonyms: FAM labled RBD4059 sodiumFAM labled Vortosiran sodium (RBD4059) a FAM labled Vortosiran sodium. Vortosiran sodium is a siRNA that inhibits the synthesis of coagulation factor XI (FXI). Vortosiran sodium shows potent inhibitory activity against mouse FXI transcripts with an IC50 of 69 pM; it exerts similar effects on common FXI transcripts from humans and monkeys, with an IC50 of 59 pM. Vortosiran sodium exhibits antithrombotic activity without impairing hemostatic function. Vortosiran sodium can be used in research related to intravascular thrombosis.
-
MK-2060
0 ImagesMK-2060 is a humanized monoclonal antibody inhibitor targeting FXI. MK-2060 can be used for atherothrombosis and venous thromboembolism research.
-
Bovine Factor XIa
0 ImagesCat. No.: HY-E70393JBovine Factor XIa is an enzyme, which is involved in the intrinsic pathway of blood coagulation. Bovine Factor XIa is highly selective and exhibits a minimal extended substrate recognition site of at least five residues long. Bovine Factor XIa is reactive as Bovine Factor IXa (HY-E70393I) does, that it cleaves all the peptides bearing factor IX activation site sequences.
-
Pyr-Pro-Arg-pNA
0 ImagesCat. No.: HY-122142CAS No.: 72194-57-1Synonyms: S-2366Pyr-Pro-Arg-pNA (S-2366) is a chromogenic peptidyl substrate, and a noncompetitive inhibitor that occupies the active sites of FXIa and FXIa-LC to block factor IX activation. Pyr-Pro-Arg-pNA functions as a hydrolyzable substrate for FXIa’s catalytic domain, human APC, murine APC, and purified plasma kallikrein.
-
FXIa/Plasma kallikrein-IN-1
0 ImagesCat. No.: HY-150519CAS No.: 1551460-43-5FXIa/Plasma kallikrein-IN-1 is an inhibitor of coagulation factor XIa (FXIa) and plasma kallikrein with Ki values of 187.70 nM and 151.6 nM, respectively. FXIa/Plasma kallikrein-IN-1 can be used in the research of thromboembolic diseases.
-
Vortosiran sodium scrambled negative control
0 ImagesCat. No.: HY-177669BSynonyms: RBD4059 sodium scrambled negative controlVortosiran sodium scrambled negative control is the sequence scrambled negative control of Vortosiran sodium.
-
Neutrophil elastase-IN-7
0 ImagesNeutrophil elastase-IN-7 is a human neutrophil elastase inhibitor with an IC50 of 0.54 μM. Neutrophil elastase-IN-7 also exhibits significant inhibitory activity against multiple coagulation proteins, with IC50 values of 8.2, 12.7, 1.2 and 5.7 μM against thrombin, FXa, FXIa and FXIIIa, respectively. Neutrophil elastase-IN-7 can be used in the research of cardiopulmonary diseases and inflammatory diseases.
-
Bemiltenase alfa
0 ImagesCat. No.: HY-P991211CAS No.: 2766038-73-5Synonyms: STSP-0601Bemiltenase alfa is a hemostatic agent targeting coagulation factor X (FX). Bemiltenase alfa activates FX and promotes the conversion of prothrombin to thrombin, and thrombin can further transform fibrinogen into fibrin, forming a stable blood clot, thus exerting hemostatic activity. Bemiltenase alfa is promising for research of bleeding symptoms with hemophilia.
-
Nonacog gamma
0 ImagesCat. No.: HY-P991213Synonyms: RixubisNonacog gamma is a coagulation factor IX (FIX) supplement. Nonacog gamma activates coagulation factor X (FX), promotes the generation of thrombin, and then converts fibrinogen into fibrin, forming a stable blood clot to exert hemostatic activity. Nonacog gamma is promising for research of hemophilia B.
-
Cy3 labled Vortosiran sodium
0 ImagesCat. No.: HY-177669DSynonyms: Cy3 labled RBD4059 sodiumCy3 labled Vortosiran (RBD4059) sodium is a Cy3 labled Vortosiran sodium. Vortosiran (RBD4059) sodium is a siRNA that inhibits the synthesis of coagulation factor XI (FXI). Vortosiran sodium shows potent inhibitory activity against mouse FXI transcripts with an IC50 of 69 pM; it exerts similar effects on common FXI transcripts from humans and monkeys, with an IC50 of 59 pM. Vortosiran sodium exhibits antithrombotic activity without impairing hemostatic function. Vortosiran sodium can be used in research related to intravascular thrombosis.
-
Factor XI-IN-2
0 ImagesCat. No.: HY-175735CAS No.: 2563884-39-7Factor XI-IN-2 is a Factor XI activation inhibitor with an IC50 of 20 nM. Factor XI-IN-2 does not directly inhibit the enzymatic activity of FXIa, but specifically binds to the FXI enzyme precursor and allosterically inhibits the process by which it is activated by FXIIa. Factor XI-IN-2 inhibits thrombosis in the rabbit arteriovenous (AV) shunt thrombosis model. Factor XI-IN-2 can be used for the study of antithrombus.
- 1
